Abeona Therapeutics Inc vs Infosys Limited — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $424.33M), while Infosys Limited trades at $12.4 (market cap $50.32B). The key difference: Infosys Limited is far larger — about 118.6× Abeona Therapeutics Inc's market cap, and Infosys Limited pays a 4.17% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | INFY | |
|---|---|---|
Market Cap | $424.33M | $50.32B |
Sector | Health | Technology |
52-Week High | $7.45 | $20.22 |
52-Week Low | $4.17 | $10.49 |
Enterprise Value | $279.23M | $48.07B |
Dividend Yield | — | 4.17% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
INFY trades at $12.53, up 1.38% today, with a bullish technical signal from moving averages. The company reported a Q1 2027 revenue miss but maintained strong operating margins of 21.1% and announced a CEO transition. Recent news highlights strategic AI collaborations, such as with Metsä Group and Sentara, driving digital transformation initiatives.
The outlook is mixed: robust profitability and AI growth offer upside, but lowered revenue guidance and competitive pressures pose risks. Analyst consensus is cautious with a $11.05 price target below the current price, suggesting limited near-term upside amid execution challenges.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →